Allan Jaffe, M.D., featured in a webinar on implementation of high-sensitivity troponin I assay

By Kelley Luedke • February 1, 2019

Share this:

Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, will be presenting a webinar on the implementation of a high-sensitivity troponin I assay on AACC. The webinar will be held February 13 from 1:00-2:00 p.m. eastern.

The Fourth Universal Definition of Myocardial Infarction recommends high-sensitivity troponin assays for routine clinical use. Compared to standard (guideline-acceptable) cardiac troponin assays, high-sensitivity troponin assays offer improved sensitivity and unparalleled precision at the low end of the measuring range. With the availability of high-sensitivity troponin I assays in the U.S., more laboratories now have the opportunity to implement these assays in clinical practice. Dr. Jaffe will discuss the latest recommendations and communications labs need to have with key clinical partners when they transition to high-sensitivity troponin assays.

Learning objectives:

• The latest recommendations for the Fourth Universal Definition of Myocardial Infarction
• How to discriminate myocardial infarction from myocardial injury when troponin values are elevated
• Common questions to expect from your clinical stakeholders and how to proactively collaborate

Learn more.

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.